HHorinouchi· @HHorinouchi · X·· 2 天前评分60
正文 · 机器翻译
🆙#ESMO26 快速口头报告：#LCSM 非转移性 🔥iTHYM：Ivonescimab 联合化疗作为复发性/转移性胸腺癌一线治疗：II期研究结果 🎙️Xue Hou 医生 🔢4156RO 🎯达到主要终点：6个月PFS率（全部19例可评估患者均无进展） 🎯ORR 83.3%，DCR 100%（n=24） ☑️NCT06750952 🔗 https://t.co/a1n3LKUDDS @OncoAlert @Larvol @myESMO @IASLC
热度 4 · 4 赞 · 0 回复 · 0 转发
会议摘要
NCT06750952NCT06750952按 - **标题 / Title：** Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial 对上
- **标题 / Title：** Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial读摘要原文 →来源：HHorinouchi · x.com